Pay in 4 interest-free payments of $24.00 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Metastatic Castration-Resistant Prostate Cancer: Critical Review of MDV-3100
Tie2 kinase inhibitor 1 (compound 5) has an IC50 of 50 μM for p38 and has moderate to excellent cellular activities (cell IC50=232 nM)[1]
Scavuzzo MA
significantly lower microvessel densities in tumors from mice treated with GSK2256098 and Paclitaxel is observed than in tumors from mice in the vehicle control group (P<0
as well as effects on the cardiovascular and endocrine systems
Dapagliflozin chin gallate Metastatic Castration-Resistant Prostate Cancer: CriticalDapagliflozin, also known as BMS 512148, is a drug used to treat type 2 diabetes approved in 2012 by FDA. Dapagliflozin inhibits subtype 2 of the sodium glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter mechanism causes blood glucose to be eliminated through the urine. In clinical trials, dapagliflozin lowered HbA1c by 0. 6 versus placebo percentage points